Ultime notizie per Lantern Pharma (NASDAQ:LTRN) Azioni

Lantern Pharma

Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.

Lantern Pharma Inc

WIIM

LTRN

LTRN stock has given up its prior gain. Lantern Pharma shares were trading higher after the company announced preclinical data for LP-184.

Lantern Pharma shares are trading higher after the company announced preclinical data for LP-184.

<ul>
<li>Independent research from Johns Hopkins validates Lantern's data used to secure the FDA Rare Pediatric Disease Designation for LP-184 in ATRT and supports planned pediatric clinical trial</li>
</ul>
Lantern Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>), a clinical-stage biopharmaceutical company leveraging advanced AI and machine learning to transform the cost, pace, and timeline of oncology drug development, today announced promising preclinical data for LP-184 in atypical teratoid rhabdoid tumors (ATRT), a rare and aggressive pediatric brain cancer. The results were presented by <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fscholar.google.com%2Fcitations%3Fuser%3DVINW8PwAAAAJ%26hl%3Den&amp;esheet=54261980&amp;newsitemid=20250529981828&amp;lan=en-US&amp;anchor=Dr.+Eric+Raabe&amp;index=1&amp;md5=aa42f6561d176d8c23bb19fe83c71cda">Dr. Eric Raabe</a> of Johns Hopkins University School of Medicine at the Society for Neuro-Oncology's 8th Biennial Pediatric Neuro-Oncology Conference held May 15-17, 2025, in San Diego, California.
The data further validates the research that supported Lantern Pharma's Rare Pediatric Disease Designation from the FDA for LP-184 in ATRT and strengthens the scientific foundation for the company's planned pediatric clinical trial expected to begin in late 2025 or early 2026.
The data demonstrated that LP-184, a next-generation acylfulvene clinical-stage drug candidate, significantly extended survival in mouse models of ATRT. In the CHLA06 model, median survival increased from 20 days in the control group to 89 days in the LP-184 treatment group, representing a 345% improvement (p&lt;0.0001). In the BT37 model, median survival increased from 68 days to 98 days (p=0.0422).

News

Lantern Pharma Announces Preclinical Data For LP-184 In Atypical Teratoid Rhabdoid Tumors, Rare And Aggressive Pediatric Brain Cancer

<h3>Gainers</h3>
<ul>
<li>Vigil Neuroscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIGL#NASDAQ">VIGL</a>) stock increased by 243.7% to $7.94 during Thursday's pre-market session. The market value of their outstanding shares is at $370.5 million. </li>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) shares moved upwards by 62.41% to $4.97. The market value of their outstanding shares is at $4.9 million. </li>
<li>Ventyx Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTYX#NASDAQ">VTYX</a>) shares increased by 13.01% to $1.73. The market value of their outstanding shares is at $123.0 million. </li>
<li>Kindly MD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) shares rose 12.79% to $25.75. The company's market cap stands at $155.0 million. </li>
<li>HOOKIPA Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOK#NASDAQ">HOOK</a>) stock increased by 11.84% to $1.7. The market value of their outstanding shares is at $20.7 million. </li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) stock increased by 10.57% to $4.81. The market value of their outstanding shares is at $2.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) shares fell 47.5% to $2.37 during Thursday's pre-market session. The company's market cap stands at $7.1 million. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) stock fell 17.55% to $0.25. The company's market cap stands at $2.7 million. </li>
<li>Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares fell 8.8% to $52.9. The company's market cap stands at $11.8 billion. </li>
<li>Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) shares decreased by 8.66% to $0.36. The company's market cap stands at $52.8 million. </li>
<li>MetaVia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTVA#NASDAQ">MTVA</a>) stock decreased by 7.49% to $0.81. The company's market cap stands at $15.8 million. </li>
<li>Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) stock decreased by 7.49% to $3.09. The market value of their outstanding shares is at $33.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BDSX

Hims & Hers Health, Inc. Class A Common Stock

HIMS

HOOK

HSDT

KDLY

MTVA

VIGL

VTAK

VTYX

Longevity Health Holdings, Inc. - Common Stock

XAGE

12 Health Care Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Inozyme Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INZY#NASDAQ">INZY</a>) stock moved upwards by 178.2% to $3.95 during Friday's regular session. The company's market cap stands at $253.7 million. As per the press release, Q1 earnings came out 2 days ago. </li>
<li>Rani Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RANI#NASDAQ">RANI</a>) stock increased by 26.52% to $0.72. The company's market cap stands at $24.2 million. As per the press release, Q1 earnings came out 3 days ago. </li>
<li>ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) shares increased by 25.62% to $22.11. The market value of their outstanding shares is at $3.7 billion. </li>
<li>Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) stock moved upwards by 25.47% to $0.28. The company's market cap stands at $40.0 million. As per the press release, Q1 earnings came out 3 days ago. </li>
<li>Agape ATP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) stock moved upwards by 25.33% to $1.88. The company's market cap stands at $94.0 million. The company's, Q1 earnings came out yesterday. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares increased by 22.8% to $5.43. The market value of their outstanding shares is at $3.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares declined by 67.3% to $0.01 during Friday's regular session. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares fell 22.48% to $0.01. </li>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) shares decreased by 19.63% to $0.65. The company's, Q2 earnings came out yesterday. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares fell 18.92% to $0.04. </li>
<li>Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) stock declined by 18.44% to $3.15. The company's market cap stands at $33.9 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Aytu BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AYTU#NASDAQ">AYTU</a>) stock declined by 18.15% to $2.12. The company's market cap stands at $13.0 million. As per the press release, Q3 earnings came out 2 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACAD

APDN

ATPC

AYTU

HCTI

INZY

NCNA

PLRZ

RANI

12 Health Care Stocks Moving In Friday's Intraday Session

Earnings

Earnings Beats

Lantern Pharma Q1 EPS $(0.42) Beats $(0.49) Estimate

ACOG

AENT

AIRI

AMAT

AREN

BABA

BCLI

BEKE

BFRI

BHST

BIRK

BLIN

BNZI

BRAG

BTBT

BTDR

CAVA

CSIQ

CYCC

DFLI

DOCS

DTIL

DTST

DUOT

EDAP

EDBL

FLNT

FTLF

GAMB

GAME

GLOB

GORV

GOSS

GSX Techedu Inc. American Depositary Shares

GOTU

HAFN

IMCC

INKT

IVVD

JAGX

KORE

KPLT

KULR

LFWD

LGCY

LMFA

LPTH

MITQ

MRSN

NICE

NRXP

NTES

NVVE

NXPL

OMER

ONDS

ORGN

PAVM

PHGE

PIII

PLBY

POCI

PPSI

PVLA

QUBT

RIME

RNXT

ROLR

SANW

SCWO

SIDU

SNYR

SOBO

SPCE

SRTS

SRXH

SWKH

TIVC

TLSI

TRAK

TSHA

TSSI

Earnings Scheduled For May 15, 2025

Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) will release its quarterly earnings report on Thursday, 2025-05-15. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Lantern Pharma to report an earnings per share (EPS) of $-0.49.
The announcement from Lantern Pharma is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Performance in Previous Earnings</h3>
During the last quarter, the company reported an EPS missed by $0.03, leading to a 4.57% drop in the share price on the subsequent day.
Here's a look at Lantern Pharma's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.51</td>
<td>-0.56</td>
<td>-0.55</td>
<td>-0.43</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.54</td>
<td>-0.42</td>
<td>-0.46</td>
<td>-0.51</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-5.0%</td>
<td>12.0%</td>
<td>-8.0%</td>
<td>-10.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747256541_0.png" alt="eps graph" />
<h3>Performance of Lantern Pharma Shares</h3>
Shares of Lantern Pharma were trading at $4.11 as of May 12. Over the last 52-week period, shares are down 33.88%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/LTRN/earnings">To track all earnings releases for Lantern Pharma visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Lantern Pharma's Earnings Outlook

The U.S. Food and Drug Administration (FDA) on Monday cleared the amendment to Lantern Pharma Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) Investigational New Drug (IND) application for the Phase 1b/2 trial of LP-184 in a genomically defined patient population of non-small <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">cell lung cancer (NSCLC)</a>.
The biomarker-focused Phase 1b/2 trial is designed to target high-risk NSCLC subtypes by evaluating LP-184 in combination with Bristol-Myers&nbsp;Squibb &amp; Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) immune checkpoint inhibitors, Opdivo (nivolumab) and Yervoy (ipilimumab) in patients with advanced NSCLC harboring KEAP1 and/or STK11 mutations and low PD-L1 expression.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45192281/exclusive-lantern-advances-breast-cancer-drug-candidate-with-fda-clearance-for-early-stage-trial" rel="noreferrer noopener">EXCLUSIVE: Lantern Advances Breast Cancer Drug Candidate With FDA Clearance For Early-Stage Trial</a>
The study is designed to assess safety, preliminary efficacy, and biomarker correlations, potentially paving a path toward accelerated development.
Lantern Pharma expects to prepare an application for a Fast Track or Accelerated Approval Designation for this patient population based on data from the planned trial and ongoing analysis from existing models.
The company said the median overall survival for newly diagnosed, advanced NSCLC with KEAP1 and/or STK11 mutations treated with checkpoint inhibitors and chemotherapy is estimated to be 15 months, and this population presents an annual market opportunity of over $2 billion.
In December 2024, the FDA granted Fast Track Designation for LP-184 for Triple-Negative Breast Cancer (TNBC). This marked the second Fast Track Designation received for LP-184 in 2024, following its designation <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42287903/lantern-pharmas-investigational-drug-candidate-lp-184-receives-second-fast-track-designation-from-" rel="noreferrer noopener">for Glioblastoma in October</a>.
LP-184 has demonstrated significant preclinical efficacy in TNBC models, including those resistant to PARP inhibitors, and recent data shows promising synergy with checkpoint inhibitors in TNBC.
In November 2024, Lantern Pharma and its wholly-owned subsidiary Starlight Therapeutics announced the presentation of new preclinical data and Phase 1b trial design for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42189336/lantern-pharma-starlight-therapeutics-present-lp-184-star-001-phase-1b-trial-design-and-preclinica" rel="noreferrer noopener">LP-184 in glioblastoma</a>.
Following the determination of the Maximum Tolerated Dose and/or Recommended Phase 2 Dose from the ongoing Phase 1a study, Starlight Therapeutics plans to initiate a Phase 1b trial evaluating LP-184/STAR-001 in two cohorts of recurrent GBM patients: one arm anticipates administration of STAR-001 as monotherapy and the other arm anticipates administration of STAR-001 in combination with spironolactone (200 mg daily).
The trial will assess safety, pharmacokinetics, and objective response using RANO 2.0 criteria. Additionally, the study will evaluate biomarkers, including PTGR1 expression, ERCC3 levels, and DNA damage markers, to help identify patients most likely to respond to treatment.
Price Action: LTRN stock traded lower by 3.02% to $3.86 premarket at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/05/45336122/trump-eyeing-nuclear-deal-with-saudi-arabia-china-and-russia-watch-closely" target="_blank" rel="noreferrer noopener">Trump Eyeing Nuclear Deal With Saudi Arabia? China and Russia Watch Closely</a></li>
</ul>

Biotech

Health Care

Market-Moving Exclusives

Exclusives

General

EXCLUSIVE: FDA Clears Lantern Pharma's Planned Phase 1b/2 Trial of LP-184 In Treatment-Resistant Lung Cancer Patients

EXCLUSIVE: Lantern Pharma Tell Benzinga 'The FDA has cleared the LP-184 investigational new drug (IND) application amendment for the treatment of a biomarker defined patient population of non-small cell lung cancer (NSCLC)'

EXCLUSIVE: Lantern Pharma Tell Benzinga 'Drug candidate LP-184 to be evaluated in combination with immune checkpoint inhibitors in biomarker-defined NSCLC patients with KEAP1 and/or STK11 mutations and low PD-L1 expression'

EXCLUSIVE: Lantern Pharma Tell Benzinga Co. Secures FDA Clerance For Planned Phase 1b/2 Trial Of LP-184 In Biomarker-Defined, Treatment-Resistant NSCLC Patients With High Unmet Clinical Need

The U.S. Food and Drug Administration (FDA) on Monday cleared Lantern Pharma Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) Investigational New Drug Application (IND) for a Phase 1b/2 trial for LP-184 in triple-negative <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">breast cancer (TNBC)</a>.
The dual approach in the clinical trial is designed to evaluate LP-184 in recurrent, advanced-stage TNBC patients through:
<ul>
<li>Monotherapy Arm: An open-label study involving approximately 30 patients with advanced-stage TNBC, focusing on dose optimization to evaluate, enhance, and optimize safety and potential efficacy for TNBC patients.</li>
<li>Combination Therapy: Evaluation of LP-184 in combination with olaparib in second-line settings for patients with advanced-stage TNBC harboring BRCA1 or BRCA2 alterations, with primary endpoints including safety and efficacy parameters that could support a pathway to regulatory approval.In preclinical studies, treating an animal model with BRCA-1 LOH and an HRD score of 63 resistant to the PARP inhibitor showed evidence of resensitization in combination with LP-184.</li>
<li>The combination phase 1b/2 trial design provides for LP-184 to be evaluated in a second-line setting in patients with advanced-stage TNBC whose primary tumor harbors alterations in BRCA1 or BRCA2.</li>
</ul>
In 2024, LP-184 received Fast Track Designations from the FDA for GBM (Glioblastoma Multiforme)&nbsp;and&nbsp;TNBC.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43741954/small-cap-os-therapies-inks-commercial-manufacture-agreements-for-its-lead-cancer-drug-for-rare-type-of-bone-cancer" rel="noreferrer noopener">Small-Cap OS Therapies Inks Commercial Manufacture Agreements For Lead Cancer Drug For Rare Type Of Bone Cancer</a>
Additionally,&nbsp;LP-184 received three Rare Pediatric Disease Designations&nbsp;for hepatoblastoma, rhabdomyosarcoma, and malignant rhabdoid tumors, in addition to its existing designation for ATRT, an ultra-rare pediatric brain tumor with the genetic hallmark of loss-of-function or <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44523410/lantern-pharma-provides-business-updates-and-fourth-quarter-year-end-2024-financial-results" rel="noreferrer noopener">deletion of the SMARCB1 gene</a>.
Lantern is conducting a Phase 1a trial that is on cohort 11, and early indications of clinical activity have been observed at higher dose levels, consistent <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44523410/lantern-pharma-provides-business-updates-and-fourth-quarter-year-end-2024-financial-results" rel="noreferrer noopener">with preliminary PK data</a>.
<ul>
<li>Dose levels 7, 8, and 9 were cleared without safety concerns during Q4 of 2024, and preliminary PK data suggest dose proportionality with exposure.</li>
<li>Enrollment at dose levels 9 and above is focused on including advanced solid tumor patients who have identified DNA damage repair mutations.</li>
<li>A broader clinical data update is slated for Q2 2025, when recruitment for the trial is expected to be finished, and complete safety and dose-response data are expected to be available.</li>
</ul>
The global TNBC market is estimated at $3-$5 billion annually, with over 300,000 new cases diagnosed worldwide yearly. While homologous recombination-deficient TNBCs are often initially treated with PARP inhibitors, resistance inevitably develops, underscoring the critical need for novel therapeutic approaches.
Price Action: LTRN stock closed at $3.54 on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/05/45179856/alnylam-delivers-q1-surprise-analysts-highlight-amvuttra-momentum-and-limited-tariff-risk" target="_blank" rel="noreferrer noopener">Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk</a></li>
</ul>

EXCLUSIVE: Lantern Advances Breast Cancer Drug Candidate With FDA Clearance For Early-Stage Trial

EXCLUSIVE: Lantern Pharma Tells Benzinga ''The phase 1b/2 clinical trial plans to evaluate LP-184 in recurrent TNBC patients as both monotherapy and in combination with olaparib'

EXCLUSIVE: Lantern Pharma Tells Benzinga Co. Advances Drug Candidate LP-184 With IND Clearance For Phase 1b/2 Trial In Triple Negative Breast Cancer

Lake Street analyst Chad Messer initiates coverage on Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) with a Buy rating and announces Price Target of $25.

Price Target

Initiation

Analyst Ratings

Lake Street Initiates Coverage On Lantern Pharma with Buy Rating, Announces Price Target of $25

Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.51) by 5.88 percent. This is a 38.46 percent decrease over losses of $(0.39) per share from the same period last year.

Earnings Misses

Lantern Pharma Q4 2024 GAAP EPS $(0.54) Misses $(0.51) Estimate

<h3>Companies Reporting Before The Bell</h3>
• Tsakos Energy Navigation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEN#NYSE">TEN</a>) is projected to report quarterly earnings at $0.40 per share on revenue of $154.43 million. 
• Worksport (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKSP#NASDAQ">WKSP</a>) is projected to report quarterly loss at $1.40 per share on revenue of $2.90 million. 
• PDS Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDSB#NASDAQ">PDSB</a>) is projected to report earnings for its fourth quarter. 
• FitLife Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTLF#NASDAQ">FTLF</a>) is estimated to report quarterly earnings at $0.20 per share on revenue of $14.95 million. 
• ADC Therapeutics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADCT#NYSE">ADCT</a>) is expected to report quarterly loss at $0.35 per share on revenue of $19.67 million. 
• Telesat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSAT#NASDAQ">TSAT</a>) is expected to report earnings for its fourth quarter. 
• Acumen Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABOS#NASDAQ">ABOS</a>) is expected to report earnings for its fourth quarter. 
• Bitfarms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BITF#NASDAQ">BITF</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $53.82 million. 
• Winnebago Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WGO#NYSE">WGO</a>) is expected to report quarterly earnings at $0.19 per share on revenue of $608.95 million. 
• BK Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BKTI#AMEX">BKTI</a>) is estimated to report quarterly earnings at $0.35 per share on revenue of $16.80 million. 
• Edap TMS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDAP#NASDAQ">EDAP</a>) is estimated to report quarterly loss at $0.11 per share on revenue of $20.83 million. 
• TriSalus Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSI#NASDAQ">TLSI</a>) is likely to report quarterly loss at $0.35 per share on revenue of $8.24 million. 
• BIO-key Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKYI#NASDAQ">BKYI</a>) is likely to report quarterly loss at $0.35 per share on revenue of $2.29 million. 
• Icecure Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCM#NASDAQ">ICCM</a>) is expected to report quarterly loss at $0.07 per share on revenue of $1.07 million. 
• Jiayin Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFIN#NASDAQ">JFIN</a>) is likely to report earnings for its fourth quarter. 
• Ascentage Pharma Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPG#NASDAQ">AAPG</a>) is projected to report earnings for its fourth quarter. 
• Urban One (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UONEK#NASDAQ">UONEK</a>) is estimated to report earnings for its fourth quarter. 
• Urban One (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UONE#NASDAQ">UONE</a>) is projected to report earnings for its fourth quarter. 
• TD Synnex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) is likely to report quarterly earnings at $2.91 per share on revenue of $14.79 billion. 
• Sachem Cap (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SACH#AMEX">SACH</a>) is projected to report quarterly loss at $0.46 per share on revenue of $14.49 million. 
• Ermenegildo Zegna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZGN#NYSE">ZGN</a>) is likely to report earnings for its Fiscal Year 2024. 
• Innate Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPHA#NASDAQ">IPHA</a>) is projected to report earnings for its Fiscal Year 2024. 
<h3>Companies Reporting After The Bell</h3>
• Dolphin Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLPN#NASDAQ">DLPN</a>) is likely to report quarterly earnings at $0.04 per share on revenue of $13.52 million. 
• Relmada Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLMD#NASDAQ">RLMD</a>) is projected to report earnings for its fourth quarter. 
• Draganfly (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPRO#NASDAQ">DPRO</a>) is projected to report quarterly loss at $0.66 per share on revenue of $1.45 million. 
• Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) is projected to report quarterly loss at $0.09 per share on revenue of $3.85 million. 
• SeaStar Medical Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICU#NASDAQ">ICU</a>) is likely to report earnings for its fourth quarter. 
• INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) is projected to report earnings for its fourth quarter. 
• TMC Metals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMC#NASDAQ">TMC</a>) is estimated to report earnings for its fourth quarter. 
• Strata Skin Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSKN#NASDAQ">SSKN</a>) is expected to report quarterly loss at $0.40 per share on revenue of $9.03 million. 
• IZEA Worldwide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IZEA#NASDAQ">IZEA</a>) is expected to report quarterly loss at $0.08 per share on revenue of $13.00 million. 
• Yxt.Com Group Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YXT#NASDAQ">YXT</a>) is expected to report earnings for its fourth quarter. 
• TSS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSSI#NASDAQ">TSSI</a>) is expected to report earnings for its fourth quarter. 
• BioRestorative Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) is likely to report quarterly loss at $0.27 per share on revenue of $475 thousand. 
• Direct Digital Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRCT#NASDAQ">DRCT</a>) is likely to report quarterly loss at $0.67 per share on revenue of $12.31 million. 
• Faraday Future (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFAI#NASDAQ">FFAI</a>) is expected to report earnings for its fourth quarter. 
• 374Water (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCWO#NASDAQ">SCWO</a>) is likely to report quarterly loss at $0.02 per share on revenue of $100 thousand. 
• Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) is estimated to report earnings for its fourth quarter. 
• Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) is projected to report quarterly loss at $0.95 per share on revenue of $920 thousand. 
• Unusual Machines (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UMAC#AMEX">UMAC</a>) is likely to report earnings for its fourth quarter. 
• BioAtla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>) is expected to report earnings for its fourth quarter. 
• Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) is projected to report quarterly loss at $0.51 per share on revenue of $1.19 million. 
• VirTra (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTSI#NASDAQ">VTSI</a>) is projected to report quarterly earnings at $0.07 per share on revenue of $8.09 million. 
• Forian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORA#NASDAQ">FORA</a>) is estimated to report quarterly earnings at $0.02 per share on revenue of $5.37 million. 
• Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) is likely to report quarterly loss at $0.31 per share on revenue of $6.20 million. 
• Beachbody Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BODI#NYSE">BODI</a>) is likely to report quarterly loss at $1.52 per share on revenue of $81.71 million. 
• Stardust Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDST#NASDAQ">SDST</a>) is expected to report earnings for its fourth quarter. 
• Valhi (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VHI#NYSE">VHI</a>) is expected to report quarterly earnings at $0.03 per share on revenue of $19.48 million. 
• Nutex Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) is projected to report quarterly earnings at $0.00 per share on revenue of $81.13 million. 
• Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) is projected to report quarterly loss at $0.05 per share on revenue of $12.80 million. 
• AAR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIR#NYSE">AIR</a>) is projected to report quarterly earnings at $0.96 per share on revenue of $679.95 million. 
• Oxford Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXM#NYSE">OXM</a>) is expected to report quarterly earnings at $1.28 per share on revenue of $383.94 million. 
• P3 Health Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIII#NASDAQ">PIII</a>) is expected to report quarterly loss at $0.17 per share on revenue of $385.80 million. 
• Co-Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODX#NASDAQ">CODX</a>) is likely to report quarterly loss at $0.34 per share on revenue of $375 thousand. 
• Argan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGX#NYSE">AGX</a>) is estimated to report quarterly earnings at $1.11 per share on revenue of $212.05 million. 
• HireQuest (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQI#NASDAQ">HQI</a>) is likely to report quarterly earnings at $0.19 per share on revenue of $9.30 million. 
• Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) is expected to report quarterly earnings at $5.65 per share on revenue of $3.52 billion. 
• Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) is likely to report quarterly loss at $0.11 per share on revenue of $294 thousand. 
• KULR Tech Gr (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KULR#AMEX">KULR</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $2.87 million. 
• Blaize Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZAI#NASDAQ">BZAI</a>) is expected to report earnings for its fourth quarter. 
• Sky Harbour Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKYH#NYSE">SKYH</a>) is expected to report quarterly loss at $0.06 per share on revenue of $4.15 million. 
• Better Choice Co (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BTTR#AMEX">BTTR</a>) is likely to report earnings for its fourth quarter. 
• Pulse Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>) is likely to report earnings for its fourth quarter. 
• Braze (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $155.25 million. 
• Lulus Fashion Lounge (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVLU#NASDAQ">LVLU</a>) is likely to report quarterly loss at $0.14 per share on revenue of $68.43 million. 
• Spectral AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDAI#NASDAQ">MDAI</a>) is expected to report quarterly loss at $0.14 per share on revenue of $6.83 million. 
• Barfresh Food Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRFH#NASDAQ">BRFH</a>) is expected to report quarterly loss at $0.01 per share on revenue of $4.17 million. 
• Abacus Global Management (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABL#NASDAQ">ABL</a>) is expected to report quarterly earnings at $0.14 per share on revenue of $30.18 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AAPG

ABOS

ADCT

BCAB

BITF

BKTI

BKYI

The Beachbody Company, Inc. Class A Common Stock

BODI

BRFH

BRTX

BRZE

BTTR

BZAI

CLSD

CODX

DLPN

DPRO

DRCT

Faraday Future Intelligent Electric Inc. - Class A Common Stock

FFAI

FORA

GEVO

GOVX

ICCM

INMB

IPHA

IRIX

IZEA

JFIN

LULU

LVLU

MDAI

NUTX

PDSB

PLSE

PSTV

RLMD

SACH

SDST

SKYH

SPRO

SSKN

TSAT

UMAC

UONE

UONEK

VTSI

WKSP

Earnings Scheduled For March 27, 2025

Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) is preparing to release its quarterly earnings on Thursday, 2025-03-27. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Lantern Pharma to report an earnings per share (EPS) of $-0.51.
Lantern Pharma bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.14, which was followed by a 12.28% increase in the share price the next day.
Here's a look at Lantern Pharma's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.56</td>
<td>-0.55</td>
<td>-0.43</td>
<td>-0.40</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.42</td>
<td>-0.46</td>
<td>-0.51</td>
<td>-0.39</td>
</tr>
<tr>
<td>Price Change %</td>
<td>12.0%</td>
<td>-8.0%</td>
<td>-10.0%</td>
<td>-25.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1743012182_0.png" alt="eps graph" />
<h3>Performance of Lantern Pharma Shares</h3>
Shares of Lantern Pharma were trading at $3.85 as of March 25. Over the last 52-week period, shares are down 57.73%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/LTRN/earnings">To track all earnings releases for Lantern Pharma visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Preview: Lantern Pharma's Earnings

Comments

Lantern Pharma

Notizie

Ultime notizie per Lantern Pharma (NASDAQ:LTRN) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO